CClinicalTrials.gg
CompletedNCT05668845Updated May 9, 2023

Paragastric Autonomic Neural Blockade as Part of Combined Anesthesia.

An interventional study of PG-ANB performed at the outset of LSG and PG-ANB performed at the end of the LSG in Opioid Use and Anesthesia Morbidity, sponsored by Universidad Simón Bolívar. Completed at 1 site in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Universidad Simón Bolívar · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the effect of early autonomic blockade on the consumption of remifentanil and halogenated anesthesia in the intraoperative period during laparoscopic sleeve gastrectomy.

Read the detailed description

Balanced general anesthesia, even if combined with local anesthesia or parietal blocks such as transversus abdominis plane (TAP), subcostal, or pararectal blocks, is insufficient to block the autonomic impulses released during most intra-abdominal visceral surgeries, especially in laparoscopic sleeve gastrectomy (LSG). These impulses are, in part, responsible for the hemodynamic changes observed during different phases of LSG and the subsequent visceral pain and associated symptoms, such as nausea and vomiting, observed in a substantial number of patients in the immediate postoperative period after LSG and other minimally invasive procedures. Visceral pain substantially impacts patients' quality of life, recovery time, nursing time allocation, and resultant risk of opioid abuse. Nausea, food intolerance, and pain are responsible for most readmissions after LSG and other bariatric procedures. Many of these patients have associated severe respiratory impairments and other comorbidities. They often need increased amounts of halogenated anesthetics, opioid analgesics, antiemetics, and other anesthetic modalities such as epidural anesthesia. A recent randomized clinical trial (RCT) demonstrated that a novel approach, namely paragastric autonomic neural blockade (PG-ANB), is safe and effective in addressing visceral pain while reducing the need for analgesics, including opioids and the decreasing nausea and vomiting in the first 24 hours after a laparoscopic sleeve gastrectomy. In an observational series, we found that by performing PG-ANB as the first step in LSG, the need for morphine-equivalent doses and halogenated anesthetics diminished, and hemodynamic stability increased while maintaining the previously reported reduction of postoperative visceral pain and associated symptoms. Similarly, when implementing a variation of the autonomic blockade targeting proper pathways as an early step in cholecystectomy, the same beneficial effects were observed in affected patients.

02

Conditions studied

  • Opioid Use
  • Anesthesia Morbidity

Keywords

  • Autonomic
  • Blockade
  • Opioids
  • Anesthetics
  • Recovery time
03

In context

Lead sponsor

Universidad Simón Bolívar is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

-all adult patients scheduled for LSG at each participating institution.

Exclusion criteria

Exclusion Criteria

  • the inability to perform a PG-ANB because of anatomical difficulties
  • the need for revisional surgery
  • the need for concomitant hiatal hernia repair or other surgical procedures
  • conversion to open surgical procedures
  • allergies to local anesthetics or medication described in the anesthesia protocol
  • intraoperative complications (e.g., visceral or vascular perforations)
  • anesthesia-related complications requiring admission to intensive care
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    PG-ANB performed at the outset of LSG

    PG-ANB is performed early in the procedure as a first step before starting the sleeve gastrectomy.

    Other: PG-ANB performed at the outset of LSG

  • Active comparator
    PG-ANB performed at the end of LSG

    PG-ANB is performed at the end of the sleeve gastrectomy

    Other: PG-ANB performed at the end of the LSG

Interventions

  • OtherPG-ANB performed at the outset of LSG

    The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four areas are adjacent to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries. This is performed at the outset of the LSG.

  • OtherPG-ANB performed at the end of the LSG

    The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four areas are adjacent to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries. This is performed at the end of the LSG\>

06

What researchers measure

Primary outcomes

  1. Intraoperative Remifentanil consumption

    The amount of remifentanil administered will be calculated based on the amount of the consumed mix and reported as total mcg and mcg/kg/min.

    Time frame: duration of the anesthesia

  2. Intraoperative consumption of the halogenated agent (sevoflurane)

    The anesthetic machine will determine the administered amount of sevoflurane (Dräger Primus) which will be reported in ml/min.

    Time frame: duration of the anesthesia

Secondary outcomes

  1. recovery from anesthesia measured by the Modified Aldrete Scale

    The Modified Aldrete scale from 0 to 15 (a higher score correlates with better recovery from anesthesia) will be assessed and recorded 15 minutes and 1 hour after surgery.

    Time frame: one hour after surgery

07

Study locations

1 site
  • clinicas Portoazul e Iberoamerica
    Barranquilla, Atlantico 080020, Colombia
08

References and documents

Publications

  • Daes J, Morrell DJ, Hanssen A, Caballero M, Luque E, Pantoja R, Luquetta J, Pauli EM. Paragastric Autonomic Neural Blockade to Prevent Early Visceral Pain and Associated Symptoms After Laparoscopic Sleeve Gastrectomy: a Randomized Clinical Trial. Obes Surg. 2022 Nov;32(11):3551-3560. doi: 10.1007/s11695-022-06257-9. Epub 2022 Sep 2. PubMed 36050617 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05668845
Lead sponsor
Universidad Simón Bolívar
Responsible party
Sponsor
First posted
Dec 30, 2022
Start date
Feb 1, 2023
Primary completion
Apr 15, 2023
Completion
May 1, 2023
Last update
May 9, 2023

Study contacts

Rafael Pantoja, MD
study chair · Universidad Simón Bolívar

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion